Top 5 Drug Type | Count |
---|---|
Small molecule drug | 37 |
Recombinant polypeptide | 2 |
Hormone | 1 |
Synthetic peptide | 1 |
Contrast agent | 1 |
Mechanism NCC inhibitors [+2] |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date04 Aug 2015 |
Target |
Mechanism DPP-4 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. South Korea |
First Approval Date27 Jun 2012 |
Target |
Mechanism PR modulators |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. European Union [+3] |
First Approval Date15 May 2009 |
Start Date29 Mar 2025 |
Sponsor / Collaborator |
Start Date12 Mar 2025 |
Sponsor / Collaborator |
Start Date07 Mar 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Ethisterone | Uterine Hemorrhage More | Approved |
Magnesium Sulfate | - | Approved |
Calf Pulmonary Surfactant | Respiratory Distress Syndrome, Newborn More | Approved |
Oxyphenonium Bromide ( M1 receptor ) | Duodenal Ulcer More | Approved |
Perflutren lipid microsphere | Contrast agents More | Approved |